SUCCESSOR-2
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 17 by
OhioHealth Riverside Methodist Hospital
Columbus, OH
- Accepting patients
- Show Principal Investigator
Northwest Medical Specialties (Gig Harbor)
Gig Harbor, WA
- Accepting patients
- Show Principal Investigator
Kaiser Permanente Orange County
Irvine Medical Center
Irvine, CA
This trial location is only accepting patients with Kaiser Permanente Insurance.
- Accepting patients
- Show Principal Investigator
Houston Methodist Hospital
Houston, TX
- Accepting patients
- Show Principal Investigator
Baylor Scott & White Hospital
Temple, TX
- Accepting patients
- Show Principal Investigator
Los Angeles Cancer Network (Los Angeles)
Los Angeles, CA
- Accepting patients
Montefiore Medical Center
Bronx, NY
- Accepting patients
- Accepting patients
- Show Principal Investigator
Dana-Farber Cancer Institute
Boston, MA
- Accepting patients
- Show Principal Investigator
Los Angeles Cancer Network (Van Nuys)
Los Angeles, CA
- Accepting patients
120 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.